Method for predicting the risk of developing side effects due to administration of a compound in which UGT1A1 enzyme itself or an intermediate metabolite is metabolized

摘要

Provided is a method for predicting the risk of developing side effects due to administration of irinotecan. Further, the present invention provides a method for reducing side effects due to administration of irinotecan. A polymorphism due to the difference in the number of repeats of the TA repeat sequence in the promoter region of the T1A1 gene and two types of polymorphisms due to single base substitution in exon 1 (base at position 211 and base at position 686) are analyzed. Predict the risk of side effects from irinotecan administration based on the analysis results. In addition, the dose of irinotecan is set for each patient according to the risk of the occurrence of side effects, and side effects due to irinotecan administration are reduced.